Endometrial Receptivity Analysis (ERA): Evidence and Limitations in ART

A 2021 study by Riestenberg et al. found that endometrial receptivity analysis (ERA) did not improve live birth rates in first ART cycles. Despite its popularity for personalizing embryo transfer timing, limited scientific evidence supports its routine use in assisted reproduction.

Key Takeaways

Endometrial Receptivity Analysis (ERA) and Its Role in ART: A 2021 Study Perspective

A large-scale 2021 study evaluating ERA in first ART cycles concluded that the test did not enhance pregnancy outcomes. Researchers found no significant increase in live birth rates, challenging the widespread adoption of ERA as a standard diagnostic tool.

Financial and Procedural Limitations of Endometrial Receptivity Testing

ERA requires an endometrial biopsy and incurs additional costs. Critics argue these factors, combined with the absence of a universally validated gene panel, limit its practicality for routine use, especially without proven long-term benefits.

Variability in ERA Gene Panels and Lack of Global Validation

At least five commercial ERA tests exist, each analyzing different genes with no standardized panel. Studies validating ERA were conducted on small, localized groups, raising concerns about their generalizability to broader patient populations.

ERA’s Efficacy in Patients with Recurrent Implantation Failure

While ERA was initially developed for patients with repeated implantation failure, the 2021 study showed that some patients with ‘abnormal’ ERA results achieved pregnancy via standard transfer. This undermines ERA’s reliability in identifying implantation window shifts.

Need for Clinical Trials to Validate Endometrial Receptivity Tests

Experts recommend evaluating ERA’s effectiveness within clinical trials rather than routine practice. Until robust evidence confirms its impact on pregnancy rates, ERA should remain experimental, particularly for patients with complex medical histories like endometriosis.

Source: Read full article